Inside, during meals. Prevention of lactation: 1 mg once (2 tablets of 0.5 mg), on the first day after childbirth. Suppression of established lactation: 0.25 mg (1/2 tablet) twice a day every 12 hours for two days (the total dose is 1 mg). In order to reduce the risk of orthostatic arterial hypotension in breastfeeding mothers, a single dose of the drug should not exceed 0.25 mg. Treatment of disorders associated with hyperprolactinemia: The recommended starting dose is 0.5 mg per week in one dose (1 tablet 0.5 mg) or in two divided doses (1/2 tablet 0.5 mg, for example on Monday and Thursday) ... The increase in the weekly dose should be carried out gradually - by 0.5 mg at monthly intervals until the optimal therapeutic effect is achieved. The therapeutic dose is usually 1 mg per week, but can range from 0.25 to 2 mg per week. The maximum dose for patients with hyperprolactinemia should not exceed 4.5 mg per week. Depending on the tolerance, the weekly dose can be taken once or divided into 2 or more doses per week. The division of the weekly dose into several doses is recommended when prescribing the drug at a dose of more than 1 mg per week. In patients with hypersensitivity to dopaminergic drugs, the likelihood of developing side effects can be reduced by starting therapy with the drug at a lower dose (for example, 0.25 mg once a week), followed by a more gradual increase (for example, an increase of 0.25 mg per week every two weeks).

Hypersensitivity to cabergoline or other components of the drug, as well as to any ergot alkaloids; dysfunction of the heart and respiration due to fibrotic changes or the presence of such conditions in history; with long-term therapy: anatomical signs of the pathology of the valve apparatus of the heart (such as thickening of the valve leaflet, narrowing of the valve lumen, mixed pathology, narrowing and stenosis of the valve), confirmed by echocardiographic examination (EchoCG) performed before the start of therapy; use in children and adolescents under the age of 16 (the safety and effectiveness of the drug have not been established); lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

In clinical studies using the drug to prevent physiological lactation (1 mg once) and to suppress lactation (0.25 mg every 12 hours for 2 days), side effects were observed in approximately 14% of women. When using the drug for 6 months at a dose of 1-2 mg per week, divided into 2 doses, for the treatment of disorders associated with hyperprolactinemia, the frequency of side effects was 68%. Side effects occurred mainly during the first 2 weeks of therapy and in most cases disappeared with the continuation of therapy or a few days after discontinuation of the drug. Side effects were usually transient, mild or moderate in severity and dose-dependent. At least once during therapy, severe side effects were observed in 14% of patients; due to side effects, treatment was discontinued in about 3% of patients. The most common side effects are presented below. On the part of the cardiovascular system: palpitations; with long-term use of the drug usually has a hypotensive effect, in some cases orthostatic arterial hypotension may occur; possibly asymptomatic decrease in LD during the first 3-4 days after childbirth (systolic - at least 20 mm Hg, diastolic - at least 10 mm Hg). From the nervous system: dizziness / vertigo, headache, fatigue, drowsiness, depression, asthenia, paresthesia, fainting, nervousness, anxiety, insomnia, impaired concentration. From the digestive system: nausea, vomiting, epigastric pain, abdominal pain, constipation, gastritis, dyspepsia, dryness of the oral mucosa, diarrhea, flatulence, toothache, irritation of the pharyngeal mucosa. Others: mastodynia, dysmenorrhea, nosebleeds, rhinitis, "hot flushes" of blood to the skin of the face, transient hemianopsia, spasms of the finger vessels and muscle cramps of the lower extremities (like other ergot derivatives, the drug can have a vasoconstrictor effect), visual impairment, flu-like symptoms, malaise, periorbital and peripheral edema, anorexia, acne, pruritus, joint pain. With long-term therapy with the use of the drug, deviation from the norm of standard laboratory parameters was noted rarely; women with amenorrhea experienced a decrease in hemoglobin levels during the first few months after menstruation was restored. In a post-marketing study, the following side effects associated with taking cabergoline were also recorded: alopecia, increased creatinine phosphokinase activity in the blood, mania, dyspnea, edema, fibrosis, abnormal liver function and abnormal liver function indicators, hypersensitivity reactions, rash, respiratory disorders, respiratory failure , valvulopathy, pathological addiction to gambling, hypersexuality, increased libido, aggressiveness, psychotic disorders, pericarditis, attacks of sudden falling asleep, weight loss or increase, nasal congestion.

There is no information on the interaction of cabergoline and other ergot alkaloids; therefore, the simultaneous use of these drugs during long-term drug therapy is not recommended. Since cabergoline has a therapeutic effect by directly stimulating dopamine receptors, it cannot be administered simultaneously with drugs acting as dopamine antagonists (phenothiazines, butyrophenones, thioxanthenes, metoclopramide, etc. they can weaken the effect of cabergoline aimed at reducing the concentration of prolactin. Like other ergot derivatives, cabergoline should not be used concomitantly with macrolide antibiotics (eg erythromycin). this can lead to an increase in the systemic bioavailability of cabergoline.

Overdose symptoms (more likely, symptoms of dopamine receptor hyperstimulation): nausea, vomiting, dyspeptic disorders, orthostatic arterial hypotension, confusion, psychosis, hallucinations. In case of an overdose, auxiliary measures should be taken to remove the non-absorbed drug (gastric lavage) and, if necessary, maintain blood pressure. Prescription of dopamine antagonists is possible.